Latest Drug development biotechnology articles and news on biotech industry leaders, emerging biotech companies in Spain

Minoryx gains FDA approval to initiate a Phase 3 clinical trial in patients with cerebral Adrenoleukodystrophy

by Ysios Capital

11 months ago
X-linked Adrenoleukodystrophy (X-ALD) patients with cerebral Adrenoleukodystrophy (cALD), CALYX, leriglitazone

Minoryx Therapeutics today announces the US Food and Drug Administration (FDA) approval of its Phase 3 clinical trial (CALYX) of lead candidate leriglitazone, to treat adult male X-linked Adrenoleukod...

Vita 34 inicia un nuevo ensayo clínico

by Secuvita

11 months ago
Tarcidomgen Kimleucel, CAR-T

Ha comenzado la inscripción en la Fase I del ensayo clínico Tarcidomgen Kimleucel. El candidato a fármaco es un CAR-T anti-CD19, un receptor de antígeno quimérico y el primer candidato en la cart...

Methylation affects how proteins work. A new technique developed at CNIO shows why

by CNIO - Centro Nacional de Investigaciones Oncológicas

11 months ago
Protein methylation

Protein methylation is a carefully controlled process that occurs in all living things, from the smallest bacteria to humans. Thanks to methylation, embryonic stem cells can develop into the different...

Un nuevo anticuerpo conjugado podría ser útil para personalizar el tratamiento de pacientes con cáncer epitelial de ovario recurrente que expresan la proteína FolRα

by Vall d’Hebron

11 months ago
(ADC) Luveltamab tazevibulin (luvelta), folato alfa (FolRα)

Los resultados del estudio fase I STRO-002 de expansión de dosis del fármaco luveltamab tazevibulin (luvelta) demuestran beneficios clínicos significativos en pacientes con cáncer de ovario con ex...

CONTACT-03: underscoring the need to identify new treatment strategies in metastatic renal cancer after disease progression with prior immunotherapy

by VHIO

11 months ago
PD-(L)1 inhibitors, atezolizumab, cabozantinib

The data obtained in the study in which VHIO participated underline the importance of prospective evaluation of re-exposure to immunotherapy before it is adopted as a standard of care.

Investigadores del ISQCH abren la puerta a la posibilidad de diseño de nuevos fármacos

by Universidad de Zaragoza

11 months ago
piperazinas

Los resultados de esta investigación son clave para poder explorar el reconocimiento molecular entre los receptores biológicos del organismo y los puntos activos de los fármacos, posibilitando la p...

3P Biopharmaceuticals lands in the United States

by 3P Biopharmaceuticals

11 months ago
contract development and manufacturing organization (CDMO), 3P Biopharmaceuticals, biological drugs

3P Biopharmaceuticals (3P), a leading contract development and manufacturing organization (CDMO) specializing in process development and cGMP manufacturing for biological drugs advances its internatio...

Diseñan un modelo matemático para estimar la eficacia de fármacos contra virus

by Universitat Rovira i Virgili

11 months ago
proteasas, virus

Dos grupos de investigación de la URV han creado un modelo de aprendizaje automático que reduciría el período de desarrollo de fármacos contra nuevos virus

Novel AKT inhibitor combined with standard hormone therapy shows promise for patients with pre-treated metastatic HR+/ HER2- breast cancer

by VHIO

10 months ago
metastatic HR+/ HER2- breast cancer, capivasertib-fulvestrant, AKT pathway

The phase III randomized multi-center CAPItello-291 assessed the efficacy and safety of novel AKT inhibitor capivasertib plus fulvestrant in patients with advanced HR+/ HER2- breast cancer who had pro...

Researchers from CIC bioGUNE reveal structural insights into the immune modulator Siglec-15 and its interaction with T cells

by CIC bioGUNE

10 months ago
Siglec-15, antígeno sialil Tn (STn).

The study, published in the journal Nature Communications, opens the door to the development of effective drug candidates that fully harness the therapeutic potential of Siglec-15. This knowledge will...

Nuage Therapeutics raises €12M in Seed Financing led by Sofinnova Partners and Asabys

by Asabys Partners

10 months ago
Asabys Partners, Nuage Therapeutics, Sofinnova Partners

Nuage Therapeutics (“Nuage”) announces today the successful closing of a €12 million Seed financing to support the development of its lead program and validate its pioneering drug discovery plat...

‘JAMA Neurology’ publishes the results from Phase 1b/2a clinical trial of the neuroprotective drug ApTOLL for ischemic stroke

by AptaTargets

10 months ago
ApTOLL, acute ischemic stroke

The results from APRIL study, previously presented at the International Stroke Conference 2023, indicate that ApTOLL showed good safety in 151 acute ischemic stroke patients.